Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

Tilray CEO Brendan Kennedy appeared on CNBC's "Mad Money" on Tuesday evening.

He told Jim Cramer that alcohol and drug companies should be looking at the cannabis space and that Canada was just the tip of the iceberg when it came to full legalization of the drug.

The Canadian cannabis producer Tilray soared Wednesday morning after CEO Brendan Kennedy laid out his company's growth prospects on CNBC's "Mad Money."

Kennedy told show host Jim Cramer on Tuesday evening that Canada was just the tip of the iceberg for full legalization when it came to marijuana.

But that's not all. He also said pharmaceutical companies needed to get in the game, noting that Tilray had already formed a strategic alliance with Novartis.

"Cannabis is a substitute for prescription painkillers, prescription opioids, and so if you're an investor in a pharmaceutical company or you're a pharmaceutical company, you have to hedge the offset from cannabis substitution," he said.

Big share gains like the one seen early Wednesday have been somewhat common for cannabis producers.

For instance, Tilray shares surged 28.95% on Tuesday on word that the company was the first to receive permission to export legal weed to the US; it plans to supply a clinical trial at the University of California at San Diego.

markets.businessinsider.com/news/stocks/weed-stocks-tilray-ceo-appears-on-cramers-mad-money-2018-9-1027547088

Of note: University of California at San Diego coupled with University of California Berkely is the scientific hub for Hound Labs.

AMG:

So, why would I post what can be considered positive for a Breathtec/Nash Pharmaceuticals deal? Because in theory it could be a good opportunity for common shareholders. In reality, it's not - As written in the Letter of Intent. The Crook & Company is simply ripping off common shareholders with a bogus valuation of Nash Pharmaceuticals.

Nash Pharma is no where near having accomplished anything that warrants a complete takeover of Breathtec. They have simply come up with arbitrary numbers to fit a narrative that hands over a V3 device literally worth 100's of millions based on Cannabix's speculative success (narrative) with THE EXACT SAME TECHNOLOGY.

Technology that Breathtec financially & diligently partnered with Cannabix to build - Sweat Equity. Now in the 11th Hour were just suppose to hand over ALL our tech/sweat equity to a zero revenues startup company (Nash Pharma) with no work product (a file cabinet with a stack of wish list projects) or revenues to show for it.

Nash Pharma is a money pit waiting to further drain common shareholders of sweat equity. There is ZERO risk for current Nash Pharma shareholders. It's all upside from the very beginning. They are litterally stealing/scheming/skimming/scamming free shares - coupled to an immediate dilution of common shareholders (Private Placement).

Common shareholders are left holding the bag time and again - for neverending PP's and Reverse Splits. What other plan is on the table for Breathtec revenues - other than sucking the life out of common shareholders?

The LOI is a very bad deal - Period. A 2 for 1 Reverse Split is a Death Knell for common shareholders that leaves no room for error on the part of Breathtec. Breathtec would need to hit a homerun it's first time at bat with one of its multi-million dollar, file cabinet, wish list, trials.

Speaking of which, management's latest report suggested a Phase II trial could average 2 million dollars. IF one believes such a thing - which I do not - their "plan" still does not address a perceived cost of Phase III clinical trials. Which averages $15 million dollars USD.

$15 million dollars USD also happens to be the same cost as Phase II trials - based on the most comprehensive 10 year study currently available. Therefore, you must know who/what the management team is were dealing with based on our "management's" history at Breathtec, and the entire Bullrun Capital portfolio.

Just yesterday, there was very serious concerns (Crook Concerns) about Bullrun Capital splattered all over the news.Given our known track record of greed and abandonment @ Breathtec, how can anyone conclude were in good hands with a Nash Pharmaceuticals takeover very poorly disguised as being acquired by Breathtec?

Excerpts from:

TORONTO, Sept. 19, 2018 (GLOBE NEWSWIRE) -- GrowMax Resources Corp. (the “Company” or “GrowMax”) (TSX-V: GRO) today commented on BullRun Capital’s value-destructing dividend scheme that would allow the activist to pocket $2.1 million of the Company’s cash reserve.

“Shareholders deserve better than BullRun’s flipflopping and back-of-the-napkin business plans,” said GrowMax CEO Stephen Keith. “A dividend for a company with a strong balance sheet is an easy short-term solution but won’t create long-term value like our PrimaSea acquisition. This is nothing but a last-ditch desperate attempt to buy shareholder votes.”

“One thing to remember in the overall analysis is that a large number of shareholders are long-term holders of GrowMax shares and acquired shares at a significant premium compared to what BullRun has acquired over the last few months. Now, BullRun wants to pay themselves back for their short-term investment, loot the treasury and take away the significant potential that our cash balance and near-term cash flow bring in these volatile capital markets. And still, BullRun and its supporters have no plan for the future of the Company.”

BullRun’s dividend scheme reveals their true intentions: They want to get their hands on GrowMax’s cash.

BullRun’s dividend scheme is value destructing and not in the best interest of shareholders.

BullRun’s ‘business plan’ lacks credibility.

www.digitaljournal.com/pr/3943038

AMG:

Anybody think there is a shred of truth in the above quotes?

Anybody think management at Breathtec has anyone's interest other than themselves in mind?

Anybody think the LOI as written will trigger litigation?

What do I know? I know I don't need a Yes/No V3 Device to Diagnose a Disease @ Breathtec Biomedical Inc.

You Can Bet Your Bottom Dollar

/////AMG